Literature DB >> 20946886

PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.

Debora Russo1, Laura Ottaggio, Ilaria Penna, Giorgia Foggetti, Gilberto Fronza, Alberto Inga, Paola Menichini.   

Abstract

PRIMA-1 has been identified as a compound that restores the transactivation function to mutant p53 and induces apoptosis in cells expressing mutant p53. Studies on subcellular distribution of the mutant p53 protein upon treatment with PRIMA-1Met, a methylated form of PRIMA-1, have suggested that redistribution of mutant p53 to nucleoli may play a role in PRIMA-1 induced apoptosis. Here, we specifically investigated the influence of PRIMA-1 on cellular localization of mutated p53-R280K endogenously expressed in tumour cells. By using immunofluorescence staining, we found a strong nucleolar redistribution of mutant p53 following PRIMA-1 treatment. This subcellular localization was associated to p53 degradation via ubiquitylation. When cells were treated with adriamycin, neither nucleolar redistribution nor mutant p53 down modulation and degradation were observed. Interestingly, cells where p53-R280K was silenced were more sensitive to PRIMA-1 than the parental ones. These results indicate that in some cellular context, the cell sensitivity to PRIMA-1 could depend on the abolition of a gain-of-function activity of the mutated p53, through a protein degradation pathway specifically induced by this compound.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946886     DOI: 10.1016/j.bbrc.2010.10.031

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

3.  PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.

Authors:  Patricia Izetti; Agnes Hautefeuille; Ana Lucia Abujamra; Caroline Brunetto de Farias; Juliana Giacomazzi; Bárbara Alemar; Guido Lenz; Rafael Roesler; Gilberto Schwartsmann; Alessandro Bersch Osvaldt; Pierre Hainaut; Patricia Ashton-Prolla
Journal:  Invest New Drugs       Date:  2014-05-20       Impact factor: 3.850

4.  p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system.

Authors:  Virginia Andreotti; Yari Ciribilli; Paola Monti; Alessandra Bisio; Mattia Lion; Jennifer Jordan; Gilberto Fronza; Paola Menichini; Michael A Resnick; Alberto Inga
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

5.  PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells.

Authors:  Nobuhisa Yoshikawa; Hiroaki Kajiyama; Kae Nakamura; Fumi Utsumi; Kaoru Niimi; Hiroko Mitsui; Ryuichiro Sekiya; Shiro Suzuki; Kiyosumi Shibata; David Callen; Fumitaka Kikkawa
Journal:  Oncol Rep       Date:  2016-03-03       Impact factor: 3.906

6.  Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.

Authors:  Kamila A Marzec; Mike Z Lin; Janet L Martin; Robert C Baxter
Journal:  Oncotarget       Date:  2015-09-29

Review 7.  PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.

Authors:  Anne Perdrix; Ahmad Najem; Sven Saussez; Ahmad Awada; Fabrice Journe; Ghanem Ghanem; Mohammad Krayem
Journal:  Cancers (Basel)       Date:  2017-12-16       Impact factor: 6.639

8.  Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.

Authors:  Mariia Patyka; Zeinab Sharifi; Kevin Petrecca; Jose Mansure; Bertrand Jean-Claude; Siham Sabri
Journal:  Oncotarget       Date:  2016-09-13

Review 9.  p53 and metabolism: from mechanism to therapeutics.

Authors:  Fernando M Simabuco; Mirian G Morale; Isadora C B Pavan; Ana P Morelli; Fernando R Silva; Rodrigo E Tamura
Journal:  Oncotarget       Date:  2018-05-04

10.  Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival.

Authors:  Giorgia Foggetti; Laura Ottaggio; Debora Russo; Carlotta Mazzitelli; Paola Monti; Paolo Degan; Mariangela Miele; Gilberto Fronza; Paola Menichini
Journal:  Biosci Rep       Date:  2019-02-19       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.